Literature DB >> 35991714

Optimal cardiovascular medical therapy: current guidelines and new developments.

Shirley Cotty Reed1, Nikita Dhir1, R Jay Widmer2.   

Abstract

Coronary artery disease is a leading cause of mortality worldwide, and patients with obstructive coronary artery disease require optimal cardiovascular medical therapy along with lifestyle modification for secondary prevention of future cardiac events. Optimal medical therapy includes antiplatelet agents, high-intensity statins, beta-blockers, angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers, aldosterone antagonists, and calcium channel blockers. There are differences in the medical therapy guidelines of the American Heart Association/American College of Cardiology and the European Society of Cardiology. In addition, there are emerging medical therapies that may be added to future guidelines with additional cardiovascular outcome benefits.
Copyright © 2022 Baylor University Medical Center.

Entities:  

Keywords:  Coronary artery disease; heart failure; optimal medical therapy

Year:  2022        PMID： 35991714      PMCID： PMC9373776          DOI： 10.1080/08998280.2022.2083903

Source DB:  PubMed          Journal:  Proc (Bayl Univ Med Cent)        ISSN： 0899-8280


  34 in total

1.  AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients with Coronary and other Atherosclerotic Vascular Disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation.

Authors:  Sidney C Smith; Emelia J Benjamin; Robert O Bonow; Lynne T Braun; Mark A Creager; Barry A Franklin; Raymond J Gibbons; Scott M Grundy; Loren F Hiratzka; Daniel W Jones; Donald M Lloyd-Jones; Margo Minissian; Lori Mosca; Eric D Peterson; Ralph L Sacco; John Spertus; James H Stein; Kathryn A Taubert
Journal:  Circulation       Date:  2011-11-03       Impact factor: 29.690

2.  Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes.

Authors:  Christopher P Cannon; Michael A Blazing; Robert P Giugliano; Amy McCagg; Jennifer A White; Pierre Theroux; Harald Darius; Basil S Lewis; Ton Oude Ophuis; J Wouter Jukema; Gaetano M De Ferrari; Witold Ruzyllo; Paul De Lucca; KyungAh Im; Erin A Bohula; Craig Reist; Stephen D Wiviott; Andrew M Tershakovec; Thomas A Musliner; Eugene Braunwald; Robert M Califf
Journal:  N Engl J Med       Date:  2015-06-03       Impact factor: 91.245

3.  2018 ACC/AHA Clinical Performance and Quality Measures for Cardiac Rehabilitation: A Report of the American College of Cardiology/American Heart Association Task Force on Performance Measures.

Authors:  Randal J Thomas; Gary Balady; Gaurav Banka; Theresa M Beckie; Jensen Chiu; Sana Gokak; P Michael Ho; Steven J Keteyian; Marjorie King; Karen Lui; Quinn Pack; Bonnie K Sanderson; Tracy Y Wang
Journal:  J Am Coll Cardiol       Date:  2018-03-29       Impact factor: 24.094

4.  The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.

Authors:  B Pitt; F Zannad; W J Remme; R Cody; A Castaigne; A Perez; J Palensky; J Wittes
Journal:  N Engl J Med       Date:  1999-09-02       Impact factor: 91.245

Review 5.  The HOPE Study (Heart Outcomes Prevention Evaluation).

Authors:  P Sleight
Journal:  J Renin Angiotensin Aldosterone Syst       Date:  2000-03       Impact factor: 1.636

Review 6.  RAS blockade with ARB and ACE inhibitors: current perspective on rationale and patient selection.

Authors:  Christian Werner; Magnus Baumhäkel; Koon K Teo; Roland Schmieder; Johannes Mann; Thomas Unger; Salim Yusuf; Michael Böhm
Journal:  Clin Res Cardiol       Date:  2008-05-03       Impact factor: 5.460

7.  Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol.

Authors:  Kausik K Ray; R Scott Wright; David Kallend; Wolfgang Koenig; Lawrence A Leiter; Frederick J Raal; Jenna A Bisch; Tara Richardson; Mark Jaros; Peter L J Wijngaard; John J P Kastelein
Journal:  N Engl J Med       Date:  2020-03-18       Impact factor: 91.245

8.  Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials.

Authors:  R Garg; S Yusuf
Journal:  JAMA       Date:  1995-05-10       Impact factor: 56.272

9.  Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome.

Authors:  Gregory G Schwartz; P Gabriel Steg; Michael Szarek; Deepak L Bhatt; Vera A Bittner; Rafael Diaz; Jay M Edelberg; Shaun G Goodman; Corinne Hanotin; Robert A Harrington; J Wouter Jukema; Guillaume Lecorps; Kenneth W Mahaffey; Angèle Moryusef; Robert Pordy; Kirby Quintero; Matthew T Roe; William J Sasiela; Jean-François Tamby; Pierluigi Tricoci; Harvey D White; Andreas M Zeiher
Journal:  N Engl J Med       Date:  2018-11-07       Impact factor: 91.245

10.  Prospective ARNI vs. ACE inhibitor trial to DetermIne Superiority in reducing heart failure Events after Myocardial Infarction (PARADISE-MI): design and baseline characteristics.

Authors:  Karola S Jering; Brian Claggett; Marc A Pfeffer; Christopher Granger; Lars Køber; Eldrin F Lewis; Aldo P Maggioni; Douglas Mann; John J V McMurray; Jean-Lucien Rouleau; Scott D Solomon; Philippe G Steg; Peter van der Meer; Margaret Wernsing; Katherine Carter; Weinong Guo; Yinong Zhou; Martin Lefkowitz; Jianjian Gong; Yi Wang; Bela Merkely; Stella M Macin; Urmil Shah; Jose C Nicolau; Eugene Braunwald
Journal:  Eur J Heart Fail       Date:  2021-04-22       Impact factor: 17.349
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.